Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism

British Journal of Cancer

Volumn 102, Issue 9, 2010, Pages 1371-1377

  Xu, C F ^a   Reck, B H ^a   Xue, Z ^a   Huang, L ^a   Baker, K L ^b   Chen, M ^b   Chen, E P ^b   Ellens, H E ^b   Mooser, V E ^a   Cardon, L R ^a   Spraggs, C F ^a   Pandite, L ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Alanine aminotransferase; Bilirubin; Pazopanib; Pharmacogenetics; Renal cell carcinoma; UGT1A1

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLUCURONOSYLTRANSFERASE 1A1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 2; PAZOPANIB; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VOTRIENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GILBERT DISEASE; HUMAN; HYPERBILIRUBINEMIA; KIDNEY CARCINOMA; LIVER DYSFUNCTION; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHARMACODYNAMICS; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

AGED; ALANINE TRANSAMINASE; ANTINEOPLASTIC AGENTS; BILIRUBIN; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; GENOTYPE; GILBERT DISEASE; GLUCURONOSYLTRANSFERASE; HUMANS; HYPERBILIRUBINEMIA; KIDNEY NEOPLASMS; LIVER; MALE; MIDDLE AGED; NEPHRECTOMY; POLYMORPHISM, GENETIC; PYRIMIDINES; SULFONAMIDES;

EID: 77951666852     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605653     Document Type: Article

References (36)

1. Aklillu E, Carrillo JA, Makonnen E, Hellman K, Pitarque M, Bertilsson L, Ingelman-Sundberg M (2003) Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 64(3): 659-669
2. Altorki N, Heymach J, Guarino M, Lee P, Felip E, Bauer T, Swann S, Roychowdhury D, Ottesen LH, Yankelevitz D (2008) Phase II study of Pazopanib (GW786034) given preoperatively in stage i-ii non-small cell lung cancer (NSCLC): a proof-of-concept study. Ann Oncol 19 (suppl 8): viii89
3. Aono S, Yamada Y, Keino H, Hanada N, Nakagawa T, Sasaoka Y, Yazawa T, Sato H, Koiwai O (1993) Identification of defect in the genes for bilirubin UDP-glucuronosyl-transferase in a patient with Crigler-Najjar syndrome type II. Biochem Biophys Res Commun 197(3): 1239-1244
4. Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, Houdt JV, Hendrickx J, Mannens G, Bohets H, Williams FM, Armstrong M, Crespi CL, Daly AK (2002) CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 64(11): 1579-1589
5. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, Oude Elferink RP, Chowdhury NR (1995) The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333(18): 1171-1175
6. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11(7): 597-607
7. Danoff TM, Campbell DA, McCarthy LC, Lewis KF, Repasch MH, Saunders AM, Spurr NK, Purvis IJ, Roses AD, Xu CF (2004) A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia. Pharmacogenomics J 4(1): 49-53
8. Fan JB, Oliphant A, Shen R, Kermani BG, Garcia F, Gunderson KL, Hansen M, Steemers F, Butler SL, Deloukas P, Galver L, Hunt S, McBride C, Bibikova M, Rubano T, Chen J, Wickham E, Doucet D, Chang W, Campbell D, Zhang B, Kruglyak S, Bentley D, Haas J, Rigault P, Zhou L, Stuelpnagel J, Chee MS (2003) Highly parallel SNP genotyping. Cold Spring Harb Symp Quant Biol 68: 69-78
9. Friedlander M, Hancock KC, Benigno B, Rischin D, Messing M, Stringer CA, Hodge JP, Ma B, Matthys G, Lager JJ (2008) Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube, and peritoneal cancers: results of a phase II study. Ann Oncol 19 (suppl 8): viii211
10. GlaxoSmithKline (2009) FDA approves GlaxoSmithKline's Votrient for advanced renal cell cancer. www.gsk.com/media/pressreleases/2009/2009- pressrelease-10113.htm
11. Han XM, Ouyang DS, Chen XP, Shu Y, Jiang CH, Tan ZR, Zhou HH (2002) Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. Br J Clin Pharmacol 54(5): 540-543
12. Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong B, Epstein RJ, Baker KL, McCann L, Crofts T, Liu Y, Pandite L, Figlin RA (2010) Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 28(3): 475-480
13. Johnson AD, Kavousi M, Smith AV, Chen MH, Dehghan A, Aspelund T, Lin JP, van Duijn CM, Harris TB, Cupples LA, Uitterlinden AG, Launer L, Hofman A, Rivadeneira F, Stricker B, Yang Q, ODonnell CJ, Gudnason V, Witteman JC (2009) Genome-wide association meta-analysis for total serum bilirubin levels. Hum Mol Genet 18(14): 2700-2710
14. Jounaidi Y, Hyrailles V, Gervot L, Maurel P (1996) Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein? Biochem Biophys Res Commun 221(2): 466-470
15. Kaplowitz N (2006) Rules and laws of drug hepatotoxicity. Pharmaco-epidemiol Drug Saf 15(4): 231-233
16. Kerb R (2006) Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 234(1): 4-33
17. Livak KJ, Marmaro J, Todd JA (1995) Towards fully automated genome-wide polymorphism screening. Nat Genet 9(4): 341-342
18. Loriot Y, Boudou-Rouquette P, Billemont B, Ropert S, Goldwasser F (2008) Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib. Ann Oncol 19(11): 1975
19. Mizuarai S, Aozasa N, Kotani H (2004) Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 109(2): 238-246
20. Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K, Sarkadi B, Bates SE (2005) Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 56(2): 161-172
21. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2): 115-124
22. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, Tsuji A, Yokoi T (2002) Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 302(2): 804-813
23. Raijmakers MT, Jansen PL, Steegers EA, Peters WH (2000) Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene. J Hepatol 33(3): 348-351
24. Rodriguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M (2005) Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun 338(1): 299-305
25. Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko CW, Sridhara R, Justice R, Pazdur R (2008) FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 13(10): 1114-1119
26. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26(28): 4672-4678
27. Singer JB, Shou Y, Giles F, Kantarjian HM, Hsu Y, Robeva AS, Rae P, Weitzman A, Meyer JM, Dugan M, Ottmann OG (2007) UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyper-bilirubinemia. Leukemia 21(11): 2311-2315
28. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schoffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY (2009) Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 27(19): 3126-3132
29. Sonpavde G, Hutson TE (2007) Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 9(2): 115-119
30. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee ES, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury D, Hawkins RE (2010) Pazopanib in locally advanced and/or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6): 1061-1068
31. Sugatani J, Yamakawa K, Yoshinari K, Machida T, Takagi H, Mori M, Kakizaki S, Sueyoshi T, Negishi M, Miwa M (2002) Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem Biophys Res Commun 292(2): 492-497
32. Tanimoto K, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K, Kumazaki T, Oue N, Yasui W, Imai K, Nakachi K, Poellinger L, Nishiyama M (2003) Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 24(11): 1779-1783
33. Taylor JD, Briley D, Nguyen Q, Long K, Iannone MA, Li MS, Ye F, Afshari A, Lai E, Wagner M, Chen J, Weiner MP (2001) Flow cytometric platform for high-throughput single nucleotide polymorphism analysis. Biotechniques 30(3): 661-666, 668-669
34. Taylor SK, Chia S, Dent S, Clemons M, Grenci P, Wang L, Oza AM, Ivy P, Pritchard K, Leighl N (2009) A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: results after completion of stage I: a trial of the Princess Margaret Hospital Phase II Consortium. J Clin Oncol 27(15s): abstract 1133
35. Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, Gurney H (2004) CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther 75(6): 529-538
36. Zucker SD, Qin X, Rouster SD, Yu F, Green RM, Keshavan P, Feinberg J, Sherman KE (2001) Mechanism of indinavir-induced hyperbilirubine-mia. Proc Natl Acad Sci USA 98(22): 12671-12676